Anagha Nadkarni, Ph.D.
Affiliations: | 2009 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
PharmacyGoogle:
"Anagha Nadkarni"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Suzan N. Kucukarslan | grad student | 2009 | University of Michigan | |
| (Implementation plans and self-monitoring of blood glucose in diabetics.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Amin A, Keshishian A, Dina O, et al. (2020) Correction to: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population. Journal of Thrombosis and Thrombolysis |
| Amin A, Keshishian A, Trocio J, et al. (2020) A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy. 26: 639-651 |
| Gupta K, Trocio J, Keshishian A, et al. (2019) Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. Bmc Cardiovascular Disorders. 19: 142 |
| Deitelzweig S, Keshishian A, Li X, et al. (2019) Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. Journal of the American Geriatrics Society |
| Amin A, Garcia Reeves AB, Li X, et al. (2019) Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. Plos One. 14: e0213614 |
| Lip GYH, Keshishian A, Li X, et al. (2018) Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 49: 2933-2944 |
| Baker CL, Dhamane AD, Mardekian J, et al. (2018) Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Advances in Therapy |
| Deitelzweig S, Guo JD, Hlavacek P, et al. (2018) Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618800806 |
| Gupta K, Trocio J, Keshishian A, et al. (2018) Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. Journal of Managed Care & Specialty Pharmacy. 1-11 |
| Li X, Keshishian A, Hamilton M, et al. (2018) Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. Plos One. 13: e0191722 |